Patient Search

KaCrole Higgins was diagnosed with breast cancer in 2020. “In May 2020, I found a lump in my breast. I cried. By June, it was diagnosed as breast cancer, triple positive, stage 1A. While getting this cancer diagnosis was devastating, it also became an opportunity. Suddenly, the cancer gave me clarity. It gave me clarity about what was important, what was good in my life, what was toxic in my life, and what I needed to do.” Click below to read more of KaCrole’s story

https://momentum.vicc.org/2022/04/cancer-gave-me-clarity/

If Landon Ryan had been diagnosed with bilateral retinoblastoma 10, 20 or 30 years ago, she might not be here today with nearly perfect vision.Thanks to recent improvements in the treatment for this rare form of cancer that almost exclusively affects children under the age of 5, the diagnosis had the power to change Landon’s life when she was 11 months old, but not to take it — or her eyesight. Click below to learn more about Landon and her story.

https://momentum.vicc.org/2022/04/brighter-outlook/

Filter By:
Search by Keyword:

Displaying 121 - 130 of 192

A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Nave Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Hematologic

Disease Sites: Hematologic

Phase: III

Investigator: Mohan, Sanjay

NCTID: NCT06479135

Protocol No: VICC-DTHEM24136

Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)

Kidney (Renal Cell)

Disease Sites: Kidney (Renal Cell)

Phase: III

Investigator: Benedetti, Daniel

NCTID: NCT06401330

Protocol No: COGAREN2231

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

Multiple Cancer Types

Disease Sites: Head/Neck, Phase I

Phase: I

Investigator: Rosenthal, Eben

NCTID:

Protocol No: VICCHNP24602

High-Resolution Specimen PET-CT Imaging for the Intraoperative Visualization of Resection Margins: An Exploratory Study

Miscellaneous

Disease Sites: Miscellaneous

Phase: I

Investigator: Topf, Michael

NCTID:

Protocol No: VICCHNP24616

A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Disease Sites: Not Available

Phase: II

Investigator: Kitko, Carrie

NCTID:

Protocol No: VICC-DTCTT24000

Pilot Study Assessment of Bone Mineral Density Changes During Treatment with Anti-PD-1 Immunotherapy Agents

Miscellaneous

Disease Sites: Miscellaneous

Phase: N/A

Investigator: Sharpe, Jessica

NCTID:

Protocol No: VICCMD25019

A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em

Thyroid

Disease Sites: Thyroid

Phase: III

Investigator: Choe, Jennifer

NCTID: NCT06475989

Protocol No: ECOGHNEA3231

ALTE2131 Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer an NCORP Phase 3 Study

Ovarian

Disease Sites: Ovarian

Phase: III

Investigator: Davis, Elizabeth

NCTID: NCT06513962

Protocol No: COGALTE2131

The CRYSTAL Study: CRYoablation Study for Outpatient Treatment of EArly-Stage Lung Cancer

Lung

Disease Sites: Lung

Phase: N/A

Investigator: Maldonado, Fabien

NCTID: NCT06593106

Protocol No: VICC-VCTHO24099

Expanded Access Protocol for Product which does not conform to the TECELRA (Afamitresgene autoleucel, suspension for intravenous infusion) Commercial Release Specification.

Sarcoma

Disease Sites: Sarcoma

Phase: N/A

Investigator: Keedy, Vicki

NCTID: NCT06617572

Protocol No: VICCSAR24510